NEW YORK and LONDON, April 03, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief Executive Officer, will present at the Jefferies Complement Symposium on April 6, 2017, in Boston,
NEW YORK and LONDON, March 30, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, clinical-stage biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has granted Fast Track designation for Coversin™ for treatment of paroxysmal
NEW YORK and LONDON, March 17, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, clinical-stage biopharmaceutical company, announced today that it will hold a Research and Development Day on April 24, 2017 in New York. The event will be hosted by members of Akari’s
NEW YORK and LONDON, March 07, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief Executive Officer, will present at the 29th Annual ROTH Conference on March 14 th , 2017, in Dana
NEW YORK and LONDON, Jan. 31, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, clinical-stage biopharmaceutical company, announced today that senior management will attend and host meetings at two upcoming conferences. Canaccord Genuity 2017 Rare Disease, Biopharma
NEW YORK and LONDON, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, clinical-stage biopharmaceutical company, has expanded its clinical and regulatory teams. In December 2016, Dr. Brihad Abhyankar joined as Head of Clinical Development and Justine Lees
NEW YORK and LONDON, Jan. 03, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has allowed on December 29th, 2016, its Investigational New Drug Application
-Phase Ib cohorts demonstrate dose effect and additional support for once daily dosing- -PAS-Coversin pre-clinical data supports once weekly dosing- -Phase II PNH patients identified with data expected 1Q17- -Eculizumab resistant PNH patient treated for over 9 months with Coversin- -New pipeline of
NEW YORK and LONDON, Nov. 11, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief Executive Officer, will attend and host meetings at two upcoming conferences.
NEW YORK and LONDON, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, clinical-stage biopharmaceutical company, announced today that an abstract has been accepted at the 58th Annual Meeting of the American Society of Hematology in San Diego, CA, from
